Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Albemarle Corporation stock logo
ALB
Albemarle
$136.96
+1.5%		$128.84
$71.25
▼
$221.00
$16.17B1.332.43 million shs478,808 shs
Albemarle Corporation stock logo
ALB
Albemarle
$136.96
+1.5%		$128.84
$71.25
▼
$221.00
$16.17B1.332.43 million shs478,808 shs
Moderna, Inc. stock logo
MRNA
Moderna
$149.48
+6.5%		$78.73
$22.28
▼
$176.66
$59.79B0.9111.49 million shs11.44 million shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Albemarle Corporation stock logo
ALB
Albemarle
-1.53%-4.49%+15.14%-21.43%+59.36%
Albemarle Corporation stock logo
ALB
Albemarle
-1.53%-4.49%+15.14%-21.43%+59.36%
Moderna, Inc. stock logo
MRNA
Moderna
+1.70%+1.04%+156.00%+207.49%+482.57%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Albemarle Corporation stock logo
ALB
Albemarle
$136.96
+1.5%		$128.84
$71.25
▼
$221.00
$16.17B1.332.43 million shs478,808 shs
Albemarle Corporation stock logo
ALB
Albemarle
$136.96
+1.5%		$128.84
$71.25
▼
$221.00
$16.17B1.332.43 million shs478,808 shs
Moderna, Inc. stock logo
MRNA
Moderna
$149.48
+6.5%		$78.73
$22.28
▼
$176.66
$59.79B0.9111.49 million shs11.44 million shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Albemarle Corporation stock logo
ALB
Albemarle
-1.53%-4.49%+15.14%-21.43%+59.36%
Albemarle Corporation stock logo
ALB
Albemarle
-1.53%-4.49%+15.14%-21.43%+59.36%
Moderna, Inc. stock logo
MRNA
Moderna
+1.70%+1.04%+156.00%+207.49%+482.57%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Albemarle Corporation stock logo
ALB
Albemarle
2.54
Moderate Buy$190.0438.76% Upside
Albemarle Corporation stock logo
ALB
Albemarle
2.54
Moderate Buy$190.0438.76% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.17
Hold$80.53-46.13% Downside

Current Analyst Ratings Breakdown

Latest ALB, MRNA, and ALB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
CLSA logo
CLSA
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeOutperform
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageHold
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
William Blair logo
William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
Bradesco Corretora logo
Bradesco Corretora
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeOutperform
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
Argus logo
Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Buy$180.00
8/25/2026
Moderna, Inc. stock logo
MRNA
Moderna
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeUnderperform ➝ Peer Perform
8/25/2026
Albemarle Corporation stock logo
ALB
Albemarle
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetNeutral$160.00 ➝ $140.00
8/25/2026
Albemarle Corporation stock logo
ALB
Albemarle
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetNeutral$160.00 ➝ $140.00
8/24/2026
Moderna, Inc. stock logo
MRNA
Moderna
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$48.00 ➝ $125.00
8/21/2026
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetUnderweight$40.00 ➝ $77.00
8/20/2026
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$50.00 ➝ $150.00
(Data available from 9/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Albemarle Corporation stock logo
ALB
Albemarle
$5.14B3.14$6.33 per share21.64$64.12 per share2.14
Albemarle Corporation stock logo
ALB
Albemarle
$5.14B3.14$6.33 per share21.64$64.12 per share2.14
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B30.70N/AN/A$22.14 per share6.75
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Albemarle Corporation stock logo
ALB
Albemarle
-$510.63M$0.27507.4012.37N/A3.09%10.96%5.39%11/4/2026 (Estimated)
Albemarle Corporation stock logo
ALB
Albemarle
-$510.63M$0.27507.4012.37N/A3.09%10.96%5.39%11/4/2026 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$7.99N/AN/AN/A-141.43%-28.30%-19.39%11/5/2026 (Estimated)

Latest ALB, MRNA, and ALB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2026Q2 2026
Albemarle Corporation stock logo
ALB
Albemarle
$3.20$3.75+$0.55$3.52$1.61 billion$1.74 billion
8/5/2026Q2 2026
Albemarle Corporation stock logo
ALB
Albemarle
$3.20$3.75+$0.55$3.52$1.61 billion$1.74 billion
7/31/2026Q2 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$2.03-$1.97+$0.06-$1.97$102.93 million$145.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Albemarle Corporation stock logo
ALB
Albemarle
$1.621.18%+1.02%600.00%30 Years
Albemarle Corporation stock logo
ALB
Albemarle
$1.621.18%+1.02%600.00%30 Years
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A

Latest ALB, MRNA, and ALB Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/21/2026
Albemarle Corporation stock logo
ALB
Albemarle
quarterly$0.411.38%9/11/20269/11/202610/1/2026
7/21/2026
Albemarle Corporation stock logo
ALB
Albemarle
quarterly$0.411.38%9/11/20269/11/202610/1/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Albemarle Corporation stock logo
ALB
Albemarle
0.22
2.09
1.35
Albemarle Corporation stock logo
ALB
Albemarle
0.22
2.09
1.35
Moderna, Inc. stock logo
MRNA
Moderna
0.09
2.29
2.18

Institutional Ownership

CompanyInstitutional Ownership
Albemarle Corporation stock logo
ALB
Albemarle
92.87%
Albemarle Corporation stock logo
ALB
Albemarle
92.87%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%

Insider Ownership

CompanyInsider Ownership
Albemarle Corporation stock logo
ALB
Albemarle
0.42%
Albemarle Corporation stock logo
ALB
Albemarle
0.42%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Albemarle Corporation stock logo
ALB
Albemarle
7,800118.00 million117.51 millionOptionable
Albemarle Corporation stock logo
ALB
Albemarle
7,800118.00 million117.51 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700399.24 million356.12 millionOptionable

Recent News About These Companies

Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough
 |  zacks.comhttps://www.zacks.com/stock/news/2983233/healthcare-etfs-to-watch-post-merck-moderna-cancer-vaccine-breakthrough?cid=cs-stocknewsapi-ft-etf_news_and_commentary-2983233
Moderna to Present at Upcoming Conferences in September 2026
 |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/moderna-present-upcoming-conferences-september-110000304.html
Moderna to Present at Upcoming Conferences in September 2026
September 1 at 7:00 AM  |  accessnewswire.comA
Moderna FY2029 EPS Lowered by Brookline Capital Markets
September 1 at 6:41 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-moderna-fy2029-eps-lowered-by-brookline-capital-markets-2026-09-01/
Van ECK Associates Corp Trims Stake in Moderna, Inc. $MRNA
September 1 at 5:20 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-van-eck-associates-corp-trims-stake-in-moderna-inc-mrna-2026-09-01/
Wellington Management Group LLP Boosts Stock Holdings in Moderna, Inc. $MRNA
September 1 at 5:12 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-wellington-management-group-llp-boosts-stock-holdings-in-moderna-inc-mrna-2026-09-01/
Empowered Funds LLC Invests $4.42 Million in Moderna, Inc. $MRNA
September 1 at 3:52 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-empowered-funds-llc-invests-442-million-in-moderna-inc-mrna-2026-09-01/
Corient Private Wealth LP Takes Position in Moderna, Inc. $MRNA
September 1 at 3:51 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-corient-private-wealth-lp-takes-position-in-moderna-inc-mrna-2026-09-01/
Moderna Stock More Than Doubled in August. Is the Stock a Buy, a Hold, or a Sell?
September 1 at 3:50 AM  |  fool.comhttps://www.fool.com/investing/2026/09/01/moderna-stock-more-than-doubled-in-august-is-the-stock-a-buy-a-hold-or-a-sell/
Moderna (MRNA) Soars 156% in August — Here’s What Propelled The Rally
September 1 at 3:24 AM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/moderna-mrna-soars-156-august-054454391.html
Best Biotech Stocks Worth Watching - August 31st
August 31 at 12:01 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/list-best-biotech-stocks-worth-watching-august-31st-2026-08-31/
After a rough stretch, mRNA gets a boost — at least for now
August 31 at 7:21 AM  |  statnews.comS
Jim Cramer Called Moderna Inc. (NASDAQ:MRNA) & Merck’s Trial Results Encouraging
August 31 at 7:21 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/jim-cramer-called-moderna-inc-053554240.html
Rakuten Investment Management Inc. Takes Position in Moderna, Inc. $MRNA
August 31 at 5:20 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-rakuten-investment-management-inc-takes-position-in-moderna-inc-mrna-2026-08-31/
United Capital Financial Advisors LLC Purchases New Stake in Moderna, Inc. $MRNA
August 31 at 5:19 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-united-capital-financial-advisors-llc-purchases-new-stake-in-moderna-inc-mrna-2026-08-31/
Alyeska Investment Group L.P. Trims Stake in Moderna, Inc. $MRNA
August 31 at 3:04 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-alyeska-investment-group-lp-trims-stake-in-moderna-inc-mrna-2026-08-31/
Moderna, Inc. (NASDAQ:MRNA) Receives Average Rating of "Hold" from Analysts
August 31 at 2:44 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30993582
Moderna, Inc. (NASDAQ:MRNA) Given Average Rating of "Hold" by Brokerages
August 31 at 2:43 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-moderna-inc-nasdaq-mrna-given-average-rating-of-hold-by-brokerages-2026-08-31/
RFK Jr. wanted ‘gold standard’ science. mRNA just delivered it
August 30 at 3:21 PM  |  msn.comhttps://www.msn.com/en-us/news/other/rfk-jr-wanted-gold-standard-science-mrna-just-delivered-it/ar-AA2bdfjv
Healthcare Stocks To Follow Now - August 30th
August 30 at 2:00 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/list-healthcare-stocks-to-follow-now-august-30th-2026-08-30/
Biotech Stocks To Keep An Eye On - August 30th
August 30 at 1:00 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/list-biotech-stocks-to-keep-an-eye-on-august-30th-2026-08-30/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Laboratory with a cryogenic quantum processor chamber, optical laser setup on a table, and data monitors displaying waveforms.
Quantum Earnings Week: Winners and Losers Are Finally Emerging
By Nathan Reiff | August 8, 2026
Albemarle logo with lithium mining, EV charging, and battery imagery highlights its role in global clean energy markets.
Albemarle’s Blowout Quarter Shows Why Lithium Still Matters
By Chris Markoch | August 9, 2026
Moderna logo displayed in a laboratory setting with a vaccine vial, petri dishes, and a microscope.
Moderna’s 177% Surge Has Investors Asking What Comes Next
By Sam Quirke | August 21, 2026
Illustration of a vial with an upward stock price chart and DNA double helix against a city skyline, symbolizing biotech growth.
2 Biotech Stocks Shaping Up for Major Breakouts
By Ryan Hasson | August 22, 2026
A home office desk with a laptop displaying a Daily Market Pulse financial report, beside a coffee mug and notebook.
MarketBeat Week in Review – 08/10 - 08/14
By MarketBeat Staff | August 15, 2026
Albemarle stock logo

Albemarle NYSE:ALB

$136.96 +1.99 (+1.47%)
As of 12:16 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. It operates through three segments: Energy Storage, Specialties and Ketjen. The Energy Storage segment offers lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride; technical services for the handling and use of reactive lithium products; and lithium-containing by-products recycling services. The Specialties segment provides bromine-based specialty chemicals, including elemental bromine, alkyl and inorganic bromides, brominated powdered activated carbon, and other bromine fine chemicals; lithium specialties, such as butyllithium and lithium aluminum hydride; develops and manufactures cesium products for the chemical and pharmaceutical industries; and zirconium, barium, and titanium products for pyrotechnical applications that include airbag initiators. The Ketjen segment offers clean fuels technologies (CFT), which is composed of hydroprocessing catalysts (HPC) together with isomerization and akylation catalysts; fluidized catalytic cracking (FCC) catalysts and additives; and performance catalyst solutions (PCS), which is composed of organometallics and curatives. The company serves the energy storage, petroleum refining, consumer electronics, construction, automotive, lubricants, pharmaceuticals, and crop protection markets. Albemarle Corporation was founded in 1887 and is headquartered in Charlotte, North Carolina.

Albemarle stock logo

Albemarle NYSE:ALB

$136.96 +1.99 (+1.47%)
As of 12:16 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. It operates through three segments: Energy Storage, Specialties and Ketjen. The Energy Storage segment offers lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride; technical services for the handling and use of reactive lithium products; and lithium-containing by-products recycling services. The Specialties segment provides bromine-based specialty chemicals, including elemental bromine, alkyl and inorganic bromides, brominated powdered activated carbon, and other bromine fine chemicals; lithium specialties, such as butyllithium and lithium aluminum hydride; develops and manufactures cesium products for the chemical and pharmaceutical industries; and zirconium, barium, and titanium products for pyrotechnical applications that include airbag initiators. The Ketjen segment offers clean fuels technologies (CFT), which is composed of hydroprocessing catalysts (HPC) together with isomerization and akylation catalysts; fluidized catalytic cracking (FCC) catalysts and additives; and performance catalyst solutions (PCS), which is composed of organometallics and curatives. The company serves the energy storage, petroleum refining, consumer electronics, construction, automotive, lubricants, pharmaceuticals, and crop protection markets. Albemarle Corporation was founded in 1887 and is headquartered in Charlotte, North Carolina.

Moderna stock logo

Moderna NASDAQ:MRNA

$149.48 +9.14 (+6.51%)
As of 12:16 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas